Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M

Aktis Oncology, Inc.

FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.
AKY-1189 (Nectin-4) granted Fast Track designation for urothelial cancer in Feb 2026; Phase 1b enrolling.
Pro forma cash of $562.1M (incl. $335.3M net from Jan 2026 IPO) expected to fund operations into 2029.
FY2025 net loss $63.7M vs $44.0M; R&D spend $67.5M (+65% YoY) driven by clinical advancement.
Collaboration revenue from Eli Lilly partnership totaled $6.5M in FY2025, up from $1.5M in FY2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aktis Oncology, Inc. reported the year ended December 31, 2025 results: revenue $6.5 million.

Period: the year ended December 31, 2025
Revenue: $6.5 million
Result: reported results

Exact text from the filing

the January 2026 IPO. The Company believes that the pro forma as adjusted cash position will fund its operations into 2029. • Collaboration revenue: Collaboration revenue was $6.5 million for the year ended December 31, 2025, compared to $1.5 million for the year ended December 31, 2024. The increase was attributable to revenue recognized under the Company’s

View on SEC.gov

Browse all earnings releases →

Aktis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-132524

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.